Comparison of the Analgesic Effectiveness of Pericapsular Nerve Block and Suprainguinal Fascia Iliac Block Application

NCT ID: NCT06672289

Last Updated: 2024-11-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-11-15

Study Completion Date

2026-11-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Suprainguinal Fascia iliac compartment outlet and Pericapsular nerve reduction, which is a routinely successful method for postoperative analgesia in anesthesia practice; the aim is to investigate information regarding postoperative pain level, analgesic consumption, patient satisfaction and discharge time after arm arthroscopy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients will be monitored with routine monitoring under operating room conditions. After the patient's baseline VAS score and vital signs are recorded, patients will be intubated after induction of general anesthesia. After the site is cleaned, a pericapsular nerve block (PENG) or suprainguinal fascia iliac block (SFIB) will be performed under USG guidance. After the procedure, the patient will be transferred to the surgical team for positioning. Blood pressure and pulse values will be recorded after the procedure and at the 30th minute of surgery.

After the patients wake up, another anesthesiologist in the recovery unit will rate the pain of patients in both groups on a scale of 0-10, using the Visual Analogue Scale (VAS) to describe their pain intensity. Heart rates and noninvasive blood pressures of patients taken to the recovery unit will be measured and recorded. Patient-controlled Analgesia (PCA) will be used for postoperative analgesia for all patients, as is routinely done, and total analgesic consumption will be evaluated. Hemodynamic data, VAS pain scores, and observed hemodynamic data of the patients were examined at 30 minutes, 60 minutes, 90 minutes, 120 minutes, and 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours in the postoperative period. Side effects will be recorded. The evaluation of the pain occurring when the hip is immobilized (VASd) and when it is moved (VASh) will be made by the anesthesiologist with VAS.

Patients' 24-hour postoperative satisfaction will be evaluated. Within the scope of the study, patients' gender, age, height, weight, ASA risk scores and operation times will be recorded.

In the statistical evaluation of the study; Analgesic consumption during the procedure, VAS scores, and analgesic consumption and patient satisfaction in the postoperative period will be evaluated and compared between groups.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hip Surgery

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pericapsular Nerve Block (PENG)

Patients will be monitored with routine monitoring under operating room conditions. After the patient's baseline VAS score and vital signs are recorded, patients will be intubated after induction of general anesthesia. After the site is cleaned, pericapsular nerve block (PENG) will be applied under USG guidance. After the procedure, the patient will be transferred to the surgical team for positioning. Blood pressure and pulse values will be recorded after the procedure and at the 30th minute of surgery. After the patients wake up, another anesthesiologist in the recovery unit will rate the pain of patients in both groups on a scale of 0-10, using the Visual Analogue Scale (VAS) to describe their pain intensity. Heart rates and noninvasive blood pressures of patients taken to the recovery unit will be measured and recorded.

No interventions assigned to this group

Suprainguinal Fascia Iliaca Block (SFIB)

Patients will be monitored with routine monitoring under operating room conditions. After the patient's baseline VAS score and vital signs are recorded, patients will be intubated after induction of general anesthesia. After the site is cleaned, suprainguinal fascia iliaca block (SFIB) will be applied under USG guidance. After the procedure, the patient will be transferred to the surgical team for positioning. Blood pressure and pulse values will be recorded after the procedure and at the 30th minute of surgery. After the patients wake up, another anesthesiologist in the recovery unit will rate the pain of patients in both groups on a scale of 0-10, using the Visual Analogue Scale (VAS) to describe their pain intensity. Heart rates and noninvasive blood pressures of patients taken to the recovery unit will be measured and recorded.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients over the age of 18 and under the age of 65 who will undergo hip arthroscopy
* ASA I-II group patients
* Patients without allergies

* Patients without psychiatric disorders
* Patients without opioid addiction
* Patients who have the ability to use the patient-controlled analgesia (PCA) device and perform VAS scoring
* Patients with no contraindications for peripheral blocks

Exclusion Criteria

* Patients who do not want to participate in the study
* Patients with uncontrolled hypertension
* Patients with chronic pain or receiving pain treatment,
* Significant Cardiac Disorder (Coronary Artery Disease, Arrhythmia, Electrocardiography Anomaly, Heart Failure, etc.)
* Patients with Diabetes Mellitus
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

TC Erciyes University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Recep Aksu

Prof. Dr. Recep AKSU

Responsibility Role PRINCIPAL_INVESTIGATOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Recep AKSU MD Recep AKSU, MD, Professor

Role: CONTACT

+90 5337461200

Yunus Emre VURAL Dr Dr. Yunus Emre VURAL, Research assistant

Role: CONTACT

+90 5063515914

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2024/162

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.